scispace - formally typeset
K

Kazuo Fushimi

Researcher at Northwestern University

Publications -  37
Citations -  2407

Kazuo Fushimi is an academic researcher from Northwestern University. The author has contributed to research in topics: Gene & Alternative splicing. The author has an hindex of 20, co-authored 37 publications receiving 2130 citations. Previous affiliations of Kazuo Fushimi include Okayama University.

Papers
More filters
Journal ArticleDOI

Inhibitory Effects of Antioxidants on Neonatal Rat Cardiac Myocyte Hypertrophy Induced by Tumor Necrosis Factor-α and Angiotensin II

TL;DR: Results indicate that TNF-alpha and Ang II cause hypertrophy in part via the generation of ROIs in cardiac myocytes.
Journal ArticleDOI

An ALS-associated Mutation Affecting TDP-43 Enhances Protein Aggregation, Fibril Formation and Neurotoxicity

TL;DR: Comparing wild-type and an ALS-associated mutant TDP-43 in vitro and in vivo provides evidence for biochemical similarities between TPD-43 and prion proteins, raising the possibility that T DP-43 derivatives may cause spreading of the disease phenotype among neighboring neurons.
Journal ArticleDOI

A Drosophila model for TDP-43 proteinopathy

TL;DR: Transgenic flies expressing hTDP-43 recapitulate important neuropathological and clinical features of human TDP- 43 proteinopathy, providing a powerful animal model for this group of devastating diseases.
Journal ArticleDOI

TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response

TL;DR: It is suggested that blocking or reversing mitochondrial damage may provide a potential therapeutic approach to these devastating diseases and uncovered a previously unknown role of LonP1 in regulating mitochondrial TDP-43 levels, but also advanced the understanding of the pathogenic mechanisms for T DP-43 proteinopathy.
Journal ArticleDOI

FUS Interacts with HSP60 to Promote Mitochondrial Damage

TL;DR: Evidence for mitochondrial localization of FUS and its induction of mitochondrial damage is provided and mitochondrial damage may be a target in future development of diagnostic and therapeutic tools for FUS-proteinopathies, a group of devastating neurodegenerative diseases.